4.7 Article

Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 147, Issue 5, Pages 1704-1719

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2020.12.641

Keywords

Olfaction; olfactory disorders; viral infections; hyposmia; anosmia; parosmia therapy; COVID-19

Ask authors/readers for more resources

Through systematic review and expert discussion, members of the Clinical Olfactory Working Group overwhelmingly recommended olfactory training as a management option for postinfectious olfactory dysfunction, while no one recommended the use of monocycline antibiotics. The diagnostic role of oral steroids was discussed, with some group members in favor of vitamin A drops as a treatment option. Further research is needed to confirm the efficacy of other therapeutic options.
Background: Respiratory tract viruses are the second most common cause of olfactory dysfunction. As we learn more about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with the recognition that olfactory dysfunction is a key symptom of this disease process, there is a greater need than ever for evidence-based management of postinfectious olfactory dysfunction (PIOD). Objective: Our aim was to provide an evidence-based practical guide to the management of PIOD (including post-coronavirus 2019 cases) for both primary care practitioners and hospital specialists. Methods: A systematic review of the treatment options available for the management of PIOD was performed. The written systematic review was then circulated among the members of the Clinical Olfactory Working Group for their perusal before roundtable expert discussion of the treatment options. The group also undertook a survey to determine their current clinical practice with regard to treatment of PIOD. Results: The search resulted in 467 citations, of which 107 articles were fully reviewed and analyzed for eligibility; 40 citations fulfilled the inclusion criteria, 11 of which were randomized controlled trials. In total, 15 of the articles specifically looked at PIOD whereas the other 25 included other etiologies for olfactory dysfunction. Conclusions: The Clinical Olfactory Working Group members made an overwhelming recommendation for olfactory training; none recommended monocycline antibiotics. The diagnostic role of oral steroids was discussed; some group members were in favor of vitamin A drops. Further research is needed to confirm the place of other therapeutic options. (J Allergy Clin Immunol 2021;147:1704-19.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available